Dual TNF-α/Cyclin D1 gene silencing with an oral polymeric microparticle system as a novel strategy for the treatment of inflammatory bowel disease

Clinical and Translational Gastroenterology

Volumn 2, Issue , 2011, Pages

  Kriegel, Christina ^a   Amiji, Mansoor M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN D1 SILENCING NANOPARTICLE IN MICROSPHERE ORAL SYSTEM; CYTOKINE; DEXTRAN SULFATE; GAMMA INTERFERON; GELATIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MICROSPHERE; MYELOPEROXIDASE; NANOPARTICLE; NANOPARTICLE IN MICROSPHERE ORAL SYSTEM; POLYCAPROLACTONE; POLYMER; RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA SILENCING NANOPARTICLE IN MICROSPHERE ORAL SYSTEM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLITIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENTERITIS; ENZYME ACTIVITY; FEMALE; GENE SILENCING; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

EID: 84859430095     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2011.1     Document Type: Article

References (47)

1. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-533. (Pubitemid 37328672)
2. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117: 514-521. (Pubitemid 46348505)
3. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205. (Pubitemid 28307304)
4. Ardizzone S, Porro GB. Biologic therapy for inflammatory bowel disease. Drugs 2005; 65: 2253-2286. (Pubitemid 41571985)
5. Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up? Curr Opin Gastroenterol 2007; 23: 395-399. (Pubitemid 46878951)
6. Stokkers PCF, Hommes DW. Novel biological therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol 2006; 9: 201-210. (Pubitemid 43853435)
7. Nakamura K, Honda K, Mizutani T et al. Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006; 12: 4628-4635. (Pubitemid 44269718)
8. Sandborn WJ. Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol 2003; 17: 105-117.
9. van Deventer SJH. New biological therapies in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2003; 17: 119-130. (Pubitemid 38001853)
10. Papa A, Mocci G, Bonizzi M et al. Biological therapies for inflammatory bowel disease: controversies and future options. Expert Rev Clin Pharmacol 2009; 2: 391-403.
11. Hoentjen F, Van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15: 2067-2073.
12. Armuzzi A, De Pascalis B, Lupascu A et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 2004; 8: 231-233. (Pubitemid 39654526)
13. Mueller C. Tumour necrosis factor in mouse models of chronic intestinal inflammation. Immunology 2002; 105: 1-8. (Pubitemid 34128034)
14. Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925. (Pubitemid 41565956)
15. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003; 327: 761-766. (Pubitemid 36315917)
16. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 2009; 27: 643-651.
17. Kortylewski M, Swiderski P, Herrmann A et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009; 27: 925-932.
18. Dickerson EB, Blackburn WH, Smith MH et al. Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer 2010; 10: 10.
19. Zhang YJ, Cristofaro P, Silbermann R et al. Engineering mucosal RNA interference in vivo. Mol Ther 2006; 14: 336-342. (Pubitemid 44184961)
20. Choi B, Hwang Y, Kwon HJ et al. Tumor necrosis factor alpha small interfering RNA decreases Herpes Simplex virus-induced inflammation in a mouse model. J Dermatol Sci 2008; 52: 87-97.
21. Peer D, Park EJ, Morishita Y et al. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008; 319: 627-630. (Pubitemid 351197066)
22. Aouadi M, Tesz GJ, Nicoloro SM et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009; 458: 1180-1184.
23. Xu D, McCarty D, Fernandes A et al. Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol Ther 2005; 11: 523-530. (Pubitemid 40353110)
24. Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm 2009; 367: 195-203.
25. Fattal E, Bochot A. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int J Pharm 2008; 364: 237-248.
26. Christian DA, Cai S, Bowen DM et al. Polymersome carriers: from self-assembly to siRNA and protein therapeutics. Eur J Pharm Biopharm 2009; 71: 463-474.
27. Bhavsar MD, Tiwari SB, Amiji MM. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release 2006; 110: 422-430. (Pubitemid 41827496)
28. Bhavsar MD, Amiji MM. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J Control Release 2007; 119: 339-348. (Pubitemid 46770879)
29. Kaul G, Amiji M. Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res 2005; 22: 951-961. (Pubitemid 40898105)
30. Bhavsar MD, Amiji MM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther 2008; 15: 1200-1209.
31. Bhavsar MD, Amiji MM. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. Aaps Pharmscitech 2008; 9: 288-294.
32. Kriegel C, Amiji M. Oral TNF-a gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J Control Release 2011; 150: 77-86.
33. Fantl V, Stamp G, Andrews A et al. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 1995; 9: 2364-2372.
34. Fu M, Wang C, Li Z et al. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004; 145: 5439-5447. (Pubitemid 39564581)
35. Alao JP, Gamble SC, Stavropoulou AV et al. The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Mol Cancer 2006; 5: 7.
36. Reis-Filho JS, Savage K, Lambros MB et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 2006; 19: 999-1099.
37. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007; 6: 24.
38. Kornmann M, Ishiwata T, Arber N et al. Increased cyclin D1 expression in chronic pancreatitis. Pancreas 1998; 17: 158-162. (Pubitemid 28345811)
39. Yang RY, Bie WJ, Haegebarth A et al. Differential regulation of D-type cyclins in the mouse intestine. Cell Cycle 2006; 5: 180-183. (Pubitemid 43131156)
40. Diez S, de Ilarduya CT. Versatility of biodegradable poly(D,L-lactic-co- glycolic acid) microspheres for plasmid DNA delivery. Eur J Pharm Biopharm 2006; 63: 188-197. (Pubitemid 43776215)
41. Tracy M. Development and scale-up of a microsphere protein delivery system. Biotechnol Prog 1998; 14: 108-115. (Pubitemid 28118271)
42. Melgar S, Karlsson A, Michaelsson EM. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 2005; 288: G1328-G1338. (Pubitemid 40741088)
43. Barbara G, Xing Z, Hogaboam CM et al. Interleukin 10 gene transfer prevents experimental colitis in rats. Gut 2000; 46: 344-349. (Pubitemid 30313385)
44. Okayasu I, Hatakeyama S, Yamada M et al. A novel method in the induction of reliable experimental acute and chronic ulcerative-colitis in mice. Gastroenterology 1990; 98: 694-702. (Pubitemid 20069706)
45. Sioud M. On the delivery of small interfering RNAs into mammalian cells. Expert Opin Drug Deliv 2005; 2: 639-651. (Pubitemid 41038677)
46. Kojouharoff G, Hans W, Obermeier F et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997; 107: 353-358. (Pubitemid 27049264)
47. Pender SL-F, Chance V, Whiting CV et al. Systemic administration of the chemokine macrophage inflammatory protein 1a exacerbates inflammatory bowel disease in a mouse model. Gut 2005; 54: 1114-1120. (Pubitemid 41025905)